ライフサイエンスコーパス: epsilon-aminocaproic acid

1 intravenous iron, erythropoietin, G-CSF, and epsilon aminocaproic acid.

2 TIP49a protein, and binding was inhibited by epsilon-aminocaproic acid.

3 d in the absence and presence of the ligand, epsilon-aminocaproic acid.

4 This process is inhibited by epsilon-aminocaproic acid.

5 This force can be reduced by the presence of epsilon-aminocaproic acid.

6 variant analysis based on an electrolyte of epsilon-aminocaproic acid.

7 gnificant reduction in total blood loss over epsilon-aminocaproic acid (-184 mL; 95% CI, -256 to -112

8 fibrinolytic agents such as tranexamic acid, epsilon-aminocaproic acid, 4-aminomethylbenzoic acid, an

9 ons in total postoperative transfusions with epsilon-aminocaproic acid (61% reduction versus placebo,

10 4-aminobutyric acid, 5-aminopentanoic acid, epsilon-aminocaproic acid, 7-aminoheptanoic acid, and t-

11 epsilon-Aminocaproic acid, a Lys analogue, effectively b

12 tibodies directed against t-PA and u-PA, and epsilon-aminocaproic acid, a lysine analog that inhibits

13 none of the reductions in IL-6 and IL-10 by epsilon-aminocaproic acid achieved statistical significa

14 n and other animal plasma in the presence of epsilon -aminocaproic acid, an active-site inhibitor tha

15 toperative hemorrhage after cardiac surgery, epsilon-aminocaproic acid, an alternative antifibrinolyt

16 epsilon-Aminocaproic acid and aprotinin had no effect on

17 Both the lysine analog epsilon-aminocaproic acid and L-proline inhibited the bi

18 stantial reductions in total blood loss with epsilon-aminocaproic acid and low-dose aprotinin (each w

19 Both epsilon-aminocaproic acid and tranexamic acid inhibit cl

20 Fibrinolysis inhibitors, including epsilon-aminocaproic acid and tranexamic acid, were effe

21 ducted a meta-analysis to compare aprotinin, epsilon-aminocaproic acid, and tranexamic acid with plac

22 Aprotinin but not epsilon-aminocaproic acid appears to attenuate the rise

23 ex concentrate, recombinant factor VIIa, and epsilon-aminocaproic acid, as potential therapeutic opti

24 ment of mice with the fibrinolytic inhibitor epsilon-aminocaproic acid before endotoxin increased bot

25 The plasminogen-specific inhibitor epsilon-aminocaproic acid blocked the tv-rENO1-plasminog

26 The lysine analog epsilon-aminocaproic acid blocks Plm-catalyzed BK genera

27 nti-HPRG antiserum, by low concentrations of epsilon-aminocaproic acid, by methylation of lysine resi

28 Both aprotinin and epsilon-aminocaproic acid decreased blood loss compared

29 These data suggest that aprotinin and epsilon-aminocaproic acid differ in their effects on the

30 of human plasminogen (Klpg) with the ligands epsilon-aminocaproic acid (EACA) and trans-4-(aminomethy

31 fibrinolytic drugs tranexamic acid (TXA) and epsilon-aminocaproic acid (EACA) are structurally simila

32 esis (CZE) method containing high amounts of epsilon-aminocaproic acid (EACA) provides a detailed and

33 The binding constants of epsilon-aminocaproic acid (EACA), 7-aminoheptanoic acid

34 that inhibited plasminogen activation, e.g., epsilon-aminocaproic acid (EACA), or plasminogen antiser

35 Treatment with epsilon-aminocaproic acid (EACA), which inhibits plasmin

36 and is inhibited by lysine analogues such as epsilon-aminocaproic acid (EACA).

37 (M66 variant) in its unliganded and ligand [epsilon-aminocaproic acid (EACA)] bound modes and the st

38 The binding is inhibited by epsilon-aminocaproic acid (epsilonACA), indicating the r

39 In contrast, epsilon-aminocaproic acid, fibrin, and fibrinogen, which

40 Antifibrinolytic drugs such as aprotinin and epsilon-aminocaproic acid have been effective in reducin

41 ell adhesion inasmuch as tranexamic acid and epsilon-aminocaproic acid inhibited cell adhesion.

42 inogen, and the presence of a lysine analog, epsilon-aminocaproic acid, inhibited the ErpP-plasminoge

43 efficacies, the considerably less-expensive epsilon-aminocaproic acid may be preferred over aprotini

44 d between 1985 and 1998 involving the use of epsilon-aminocaproic acid (n=9) or aprotinin (n=46) in p

45 eeding event (n = 54 unique subjects; n = 18 epsilon aminocaproic acid, n = 35 tranexamic acid, and n

46 study examined the effects of aprotinin and epsilon-aminocaproic acid on plasma levels of proinflamm

47 The presence of epsilon-aminocaproic acid only slightly inhibited bindin

48 brinolysis by the indirect plasmin inhibitor epsilon-aminocaproic acid or by alpha2AP restored thromb

49 tients transfused was similarly reduced with epsilon-aminocaproic acid (OR, 0.32; 95% CI, 0.15 to 0.6

50 -blind study to receive high-dose aprotinin, epsilon-aminocaproic acid, or saline placebo.

51 Saturating levels of epsilon-aminocaproic acid reduced the affinity of SK for

52 ding and activation by CRT were inhibited by epsilon-aminocaproic acid, suggesting that an internal l

53 ed TAFIa from human serum in the presence of epsilon -aminocaproic acid was also developed.

54 yclo(Phe-4-Cpa-Gln-D-Phe-Pro-Asp-Aca) (Aca = epsilon-aminocaproic acid), which did not contain tyrosi

55 nducted in the presence of the lysine analog epsilon-aminocaproic acid, which precludes apo(a)-B100 a